AWM
AXDX

Apollon Wealth Management’s Accelerate Diagnostics AXDX Stock Holding History

Apollon Wealth Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,200
Closed -$167K – 768
2021
Q4 		$167K Buy
+3,200
New +$178K 0.01% 724

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Apollon Wealth Management's AXDX Position: Q1 2022 in Review

Apollon Wealth Management sold out of Accelerate Diagnostics (AXDX) in Q1 2022, closing a stake of 3,200 shares — an estimated $167K sold.

Apollon Wealth Management first reported a position in AXDX in Q4 2021 and held it in 1 quarter. The position peaked at $167K in Q4 2021. 106 funds tracked by Wall St. Rank hold AXDX as of Q1 2022.

  • Apollon Wealth Management reported no remaining Accelerate Diagnostics position as of Q1 2022 after selling out during the quarter.
  • Apollon Wealth Management sold 3,200 Accelerate Diagnostics shares in Q1 2022, an estimated $167K.
  • Apollon Wealth Management first reported a position in Accelerate Diagnostics in Q4 2021 and held it in 1 quarter.
  • Apollon Wealth Management's Accelerate Diagnostics position peaked at $167K in Q4 2021.
  • 106 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2022.

Based on Apollon Wealth Management's 13F filing for Q1 2022, filed 16 May 2022.